-
3 weeks ago | 
thepathologist.com | Helen Bristow
Imagine having access to a database of carefully curated, peer-reviewed tumor pathology images from all round the world. Now imagine that access is publicly available, completely free, and you don’t even need to register your details!Now, leaving imagination aside, go visit the World Tumor Registry (WTR).
-
1 month ago | 
thepathologist.com | Helen Bristow
With lung cancer continuing to be the leading cause of cancer mortality in Canada and many other countries, and precision medicine taking over every stage of treatment, the stakes for timely and accurate molecular diagnostics are more important than ever.
-
1 month ago | 
thepathologist.com | Helen Bristow
How did your career lead you to your current position? I discovered a passion for research during my undergraduate years and time in the molecular biology department at Princeton, where I studied genes involved in the cell cycle in a model yeast system. My journey in science continued as an MD and PhD student in the Medical Scientist Training Program at Harvard, where I developed a deep interest in oncology.
-
1 month ago | 
thepathologist.com | Helen Bristow
What drew you to both pathology and education? I was always interested in the combination and application of the basic sciences in medicine. I found that studying the mechanisms of diseases was so instructive to me in terms of understanding how we diagnose and treat them. Equally, I was that kid in high school who happily volunteered to tutor other students. Prior to medical school I did some work for the education company, Kaplan Test Prep.
-
1 month ago | 
thepathologist.com | Helen Bristow
Would you want a robot to take your blood sample? The inventors of Aletta, the world’s first autonomous robotic phlebotomy device, think you might – especially when you hear how accurate it is. And, with phlebotomists in increasingly short supply, visiting the robot assistant might be preferable to having a long wait time for a short procedure. AI-driven automation is now commonplace in pathology labs – but could it also represent the future of clinical care?
-
1 month ago | 
thepathologist.com | Helen Bristow
In a recent newsletter reporting on job cuts in US health agency divisions, we asked readers of The Pathologist, “How might cuts to disease surveillance programs affect a nation’s health?”Here is a selection of the responses. It will take years to right the ship“We all know the answer to your question. Such cuts will severely damage our ability to protect the health of our country. However, there is much more to this than the cuts in funding and jobs at HHS, NIH, and so on.
-
2 months ago | 
thepathologist.com | Helen Bristow
New research, presented at the AD/PD 2025 meeting in Vienna, has revealed a potential biomarker for diagnosis and monitoring of Parkinson’s disease (PD). The study – a collaboration between Merck and the Michael J. Fox Foundation for Parkinson’s Research (MJFF) – shows an initial proof of concept for a novel α-synuclein positron emission tomography (PET) tracer that visualizes α-synuclein pathology in the brain of patients with Parkinson’s disease. We connected with Robert E.
-
2 months ago | 
thepathologist.com | Helen Bristow
What drew you to pathology? My initial ambition was to become a surgeon. At medical school I took a few electives in surgery where I realised I was curious about what happened to my surgical specimens and what they could reveal about the downstream impact of my surgeries. So, thinking it would make me a better surgeon, I opted for an elective in pathology.
-
2 months ago | 
thepathologist.com | Helen Bristow
In the states of Illinois and Indiana, a network of private laboratories, headed up by Sam Terese, is way ahead of the curve. Having made the decision to fully digitize its histopathology workflow back in 2017, Alverno Laboratories is a true pioneer of computational pathology, Stateside. The Pathologist sat down with Terese to find out why – and how – Alverno took the digital pathology plunge. I've been in the laboratory field for a little over 45 years.
-
2 months ago | 
thepathologist.com | Helen Bristow
Researchers at the University of Liverpool have launched an initiative to advance our understanding of cancers of the eye. The Eye Cancer Artificial Intelligence Digital (EYE-CAN-AID) Bioresource, combines a digital eye cancer biobank with AI-driven analysis. It is hoped the resource will help to develop better diagnostic tools to inform personalized treatments.
